ACTS Connection

November 2026

Issue 1

Letter from the President

Dear ACTS Members,

Nominations for Fellow of ACTS are due today. Please make sure your nominations are submitted before you read further! The Fellows program is part of our ACTS strategic plan, under the broad goal of further increasing membership value. That goal also includes making the invisible visible through communication with our members. I have two specific points to make visible today.

First, the structure of ACTS has been challenging to understand, perhaps even for those in the know. In an effort to demonstrate our structure, we now have an organizational chart. This is especially important because we are in a time of change in concert with our strategic plan. If you’ve wondered about what is included in this society, please review the org chart.

A major feature of our ACTS structure is our special interest groups, or SIGs. SIGs are a key ACTS activity, with over 1,000 members in our 12 active SIGs. SIGs meet virtually through the year and in person at Translational Science. SIGs are especially important because they bring together people who focus on the same topic but span both institutions and career stages. SIGs have their own leadership and a private virtual space on ACTS Connect (formerly called Tradewing) for discussions and file sharing. To see information on our current SIGs – or even to join one, click here. Finally, I also want to draw your attention to a brand-new SIG, the Research Commercialization and Entrepreneurship SIG. This SIG was proposed by individuals across multiple ACTS member institutions with the objective of advancing commercialization as an integral component of translational science. The SIG’s ACTS Connect community and additional information are coming soon.

In translational community,

Felicity T. Enders, PhD, MPH


ACTS Updates

Translational Science 2027 Award Nominations Close November 18

Less than a week left to submit your nominations for the Translational Science 2027 awards! Help us identify nominees for the most outstanding investigators, educators, and trainees from across the clinical and translational science consortium. The nominations portal closes on Tuesday, November 18 at 11:59 PM PT. Visit our website for the full descriptions and criteria for each of our awards categories.

Translational Science 2027 will be held in Washington, DC from April 20-23, 2027. The time to register is closer than you think. Start making your plans today!

Submit a Nomination

ACTS Board of Directors Call for Nominations

The call for nominations for the ACTS board of directors is open! All institutional and individual members of ACTS are eligible to run for the board with terms beginning April 2027. The nomination submission deadline is Monday, November 30 and ACTS members can be self-nominated or can nominate another member.

A full list of Director-at-Large leadership criteria is available to view here. Please don't hesitate to contact info@actscience.org with any questions about the nominations process.

Submit a Nomination

JCTS Editor-in-Chief Applications Open through January 12, 2027

The Journal of Clinical and Translational Science (JCTS) is accepting applications for the position of Editor-in-Chief that will take effect January 1, 2028. The Editor-in-Chief reports to the ACTS Board of Directors and is responsible for the strategic direction and editorial scope of JCTS. Ideal candidates will have distinguished research and publication records, broad-based backgrounds in clinical and translational science, and hold high standing among peers across institutions.

All candidates for the position of Editor-in-Chief of JCTS are asked to submit your interest along with a curriculum vitae and completed questionnaire to info@actscience.org by Tuesday, January 12, 2027. Learn more information about the role here. For additional information about JCTS, candidates are welcome to contact JCTS Editor-in-Chief Chris Lindsell, PhD at JCTS-EIC@actscience.org.

Learn More

Three Minute Thesis® Signups Now Open

The annual Three Minute Thesis (3MT®) competition will return for Translational Science 2027! The 3MT is an academic research communication competition developed by The University of Queensland (UQ), Australia that cultivates students’ academic, presentation, and research communication skills. By participating in the 3MT held during Translational Science 2027, participants will have the opportunity to take part in a highly respected, globally recognized competition to demonstrate their mastery of research communication skills, an essential skill required in all areas of the field. Win or lose, participating in this competition is an incredible learning opportunity to boost presentation confidence, meet a supportive group of like-minded peers, and add a great activity to their resume.

Applications are open through Monday, January 18, 2027 for each of the three categories: Predoctoral Trainees, Postdoctoral Trainees, and Early Career Faculty Scholars. Visit our website for full competition rules and judging criteria.

Learn More

Announcement: NIH Proposes Modernizing its Data and Safety Monitoring Policy

NIH is proposing updates to its Data and Safety Monitoring Policy to reflect the evolving clinical research landscape while maintaining its commitment to participant safety and the quality and integrity of research data.

NIH is releasing a Draft Updated Policy for Data and Safety Monitoring for public comment. The proposed updates aim to:

  • Harmonize data and safety monitoring requirements across NIH.
  • Reduce administrative burden that is not commensurate with research risk.
  • Establish meaningful expectations to ensure robust, reliable data and sound scientific conclusions.

The draft policy was informed by feedback received through NIH’s initial stakeholder engagement efforts.

Submit Your Comments

NIH invites stakeholders and the public to review the draft policy and provide feedback. Comments must be submitted through the NIH Public Comment Form by January 6, 2027.

Questions may be directed to SciencePolicy@od.nih.gov.

This announcement was originally sent to the NIH Office of Science Policy's listserv. If you are not yet a subscriber to this listserv, please sign up here.


Partner News

News from the Hill - Midterm Elections Special

The Tuesday, November 3, mid-term elections brought sweeping change to Capitol Hill and national politics. The American people delivered a stern rebuke of the status quo by electing Democrats across the nation (and in a notable majority of state races). As votes were counted, the outcome became clear early in the evening, and it was obvious to all (including the White House) that in January the Democrats would enjoy a tremendous majority in the House (ending the razor-thin control that has stymied the legislative process) and the Senate would have at least a four-vote Democratic majority.

Read More

"News from the Hill" briefings are generously provided by our advocacy partners from the Health and Medicine Counsel


Stories from our Members

UK HealthCare patient among first in US to receive experimental lupus treatment

Angela Rondón-Colón, 43, was an active mother of three young boys when she received a life-altering lupus diagnosis at 25-years-old. Now, she has a second chance at a fresh start. 

Rondón-Colón was diagnosed with systemic lupus erythematosus (SLE), the most severe and common type of lupus, which affects multiple organ systems in the body. 

At least 1.5 million Americans and five million people worldwide have a form of lupus, according to the Lupus Foundation of America. 

She is now the second patient in the U.S. to receive an experimental treatment for SLE.

Read More

Mindfulness-Based Therapy May Change Brain Responses to Drug Cues in People With Opioid Use Disorder, Mount Sinai Study Finds

Mindfulness-Oriented Recovery Enhancement (MORE), a behavioral therapy used alongside medication treatment, may help people with opioid use disorder respond differently to drug-related cues and natural rewards, according to a randomized clinical trial led by researchers at the Icahn School of Medicine at Mount Sinai. The findings offer insight into how MORE may reduce opioid craving and support recovery.

Published in JAMA Psychiatry, the study used brain imaging to examine how MORE affects the prefrontal cortex, which helps regulate behavior, make decisions, and evaluate rewards. After eight weeks, participants who received MORE showed changes in brain activity while regulating their responses to drug-related images. These changes were associated with greater reductions in craving. At a follow-up visit approximately four months after treatment, participants receiving MORE also had greater increases in the duration of abstinence than those receiving a comparison therapy. 

Read More

Want to see your institution's stories featured in this section? Fill out our story submission form to share your recent articles!


Engage with ACTS

Special Interest Groups

ACTS offers its members the opportunity to participate in Special Interest Groups (SIGs) related to the field of clinical research and translational science. SIGs connect individuals who share similar goals and interests, providing a channel to network and participate in knowledge and resource sharing among peers.

Career Center

We're excited to announce a quality of use upgrade for the ACTS Career Center! We have added a dual single sign on option for our Career Center. Your current membership login credentials now allow you to log directly into our Career Center. Try it out here.

Don't forget ACTS members get a 50% discount on job postings - just use code ACTSMEMBER to save!